|
1
|
Smith CJ, Volkert WA and Hoffman TJ:
Gastrin releasing peptide (GRP) receptor targeted
radiopharmaceuticals: A concise update. Nucl Med Biol. 30:861–868.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thompson IM, Pauler DK, Goodman PJ, Tangen
CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford
ED, et al: Prevalence of prostate cancer among men with a
prostate-specific antigen level < or =4.0 ng per milliliter. N
Engl J Med. 350:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scardino PT, Weaver R and Hudson MA: Early
detection of prostate cancer. Hum Pathol. 23:211–222. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bubendorf L, Schöpfer A, Wagner U, Sauter
G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns
of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol.
31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang H, Abiraj K, Thorek DL, Waser B,
Smith-Jones PM, Honer M, Reubi JC and Maecke HR: Evolution of
bombesin conjugates for targeted PET imaging of tumors. PLoS One.
7:e440462012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bodei L, Paganelli G and Mariani G:
Receptor radionuclide therapy of tumors: A road from basic research
to clinical applications. J Nucl Med. 47:375–377. 2006.PubMed/NCBI
|
|
7
|
Ginj M, Zhang H, Waser B, Cescato R, Wild
D, Wang X, Erchegyi J, Rivier J, Mäcke HR and Reubi JC:
Radiolabeled somatostatin receptor antagonists are preferable to
agonists for in vivo peptide receptor targeting of tumors. Proc
Natl Acad Sci USA. 103:16436–16441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cescato R, Maina T, Nock B, Nikolopoulou
A, Charalambidis D, Piccand V and Reubi JC: Bombesin receptor
antagonists may be preferable to agonists for tumor targeting. J
Nucl Med. 49:318–326. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varasteh Z, Velikyan I, Lindeberg G,
Sörensen J, Larhed M, Sandström M, Selvaraju RK, Malmberg J,
Tolmachev V and Orlova A: Synthesis and characterization of a
high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted
tumor imaging. Bioconjug Chem. 24:1144–1153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varasteh Z, Aberg O, Velikyan I, Lindeberg
G, Sörensen J, Larhed M, Antoni G, Sandström M, Tolmachev V and
Orlova A: In vitro and in vivo evaluation of a (18)F-labeled high
affinity NOTA conjugated bombesin antagonist as a PET ligand for
GRPR-targeted tumor imaging. PLoS One. 8:e819322013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Varshney R, Hazari PP, Fernandez P, Schulz
J, Allard M and Mishra AK: 68Ga-labeled bombesin analogs for
receptor-mediated imaging. Theranostics, Gallium-68, and Other
Radionuclides: A Pathway to Personalized Diagnosis and Treatment.
Baum RP and Rösch F: Springer; Heidelberg, New York, Dordrecht,
London: pp. 221–256. 2013, View Article : Google Scholar
|
|
12
|
Varasteh Z, Rosenström U, Velikyan I,
Mitran B, Altai M, Honarvar H, Rosestedt M, Lindeberg G, Sörensen
J, Larhed M, et al: The effect of mini-PEG-based spacer length on
binding and pharmacokinetic properties of a 68Ga-labeled
NOTA-conjugated antagonistic analog of bombesin. Molecules.
19:10455–10472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varasteh Z, Mitran B, Rosenström U,
Velikyan I, Rosestedt M, Lindeberg G, Sörensen J, Larhed M,
Tolmachev V and Orlova A: The effect of macrocyclic chelators on
the targeting properties of the 68Ga-labeled gastrin releasing
peptide receptor antagonist PEG2-RM26. Nucl Med Biol. 42:446–454.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Müller C and Schibli R: Single photon
emission computed tomography tracer. Molecular Imaging in Oncology.
Schober O and Riemann B: Springer; Heidelberg, New York, Dordrecht,
London: pp. 65–105. 2013, View Article : Google Scholar
|
|
15
|
Ginj M and Maecke HR: Radiometallo-labeled
peptides in tumor diagnosis and therapy. Metal Ions in Biological
Systems: Metal Complexes in Tumor Diagnosis and as Anticancer
Agents. Sigel A and Sigel H: 42. FontisMedia SA and Marcel Dekker,
Inc; pp. 109–142. 2004
|
|
16
|
Heppeler A, André JP, Buschmann I, Wang X,
Reubi JC, Hennig M, Kaden TA and Maecke HR: Metal-ion-dependent
biological properties of a chelator-derived somatostatin analogue
for tumour targeting. Chemistry. 14:3026–3034. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartholomä MD, Louie AS, Valliant JF and
Zubieta J: Technetium and gallium derived radiopharmaceuticals:
Comparing and contrasting the chemistry of two important
radiometals for the molecular imaging era. Chem Rev. 110:2903–2920.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lozza C, Navarro-Teulon I, Pèlegrin A,
Pouget JP and Vivès E: Peptides in receptor-mediated radiotherapy:
From design to the clinical application in cancers. Front Oncol.
3:2472013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu B, Varasteh Z, Orlova A, Andersson K,
Larhammar D and Björkelund H: Detecting ligand interactions with G
protein-coupled receptors in real-time on living cells. Biochem
Biophys Res Commun. 441:820–824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eckelman WC, Kilbourn MR and Mathis CA:
Specific to nonspecific binding in radiopharmaceutical studies:
It's not so simple as it seems! Nucl Med Biol. 36:235–237. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tolmachev V and Orlova A: Influence of
labelling methods on biodistribution and imaging properties of
radiolabelled peptides for visualisation of molecular therapeutic
targets. Curr Med Chem. 17:2636–2655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heppeler A, Froidevaux S, Macke HR,
Jermann E, Behe M, Powell P and Hennig M: Radiometal-labelled
macrocyclic chelator-derivatised somatostatin analogue with superb
tumour targeting properties and potential for receptor rmediated
internal radiotherapy. Chemistry. 5:1974–1981. 1999. View Article : Google Scholar
|
|
23
|
Deshmukh MV, Voll G, Kühlewein A, Mäcke H,
Schmitt J, Kessler H and Gemmecker G: NMR studies reveal structural
differences between the gallium and yttrium complexes of
DOTA-D-Phe1-Tyr3-octreotide. J Med Chem. 48:1506–1514. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Broan CJ, Cox JPL, Craig AS, Kataky R,
Parker D, Harrison A, Randall A and Ferguson GJ: Structure and
solution stability of indium and gallium complexes of
1,4,7-triazacyclononanetriacetate and of yttrium complexes of
1,4,7,10-tetraazacyclododecanetetraacetate and related ligands:
Kinetically stable complexes for use in imaging and
radioimmunotherapy. X-Ray molecular structure of the indium and
gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid.
J Chem Soc Perkin Trans. 2:87–99. 1991. View Article : Google Scholar
|
|
25
|
Matthews RC, Parker D, Ferguson G, Kaitner
B, Harisson A and Royle L: Synthesis and structure of stable indium
and gallium complexes of
(R)-1,4,7-tris(2′-methylcarboxymethyl)-triazacyclononane.
Polyhedron. 10:1951–1953. 1991. View Article : Google Scholar
|
|
26
|
Abiraj K, Mansi R, Tamma ML, Fani M,
Forrer F, Nicolas G, Cescato R, Reubi JC and Maecke HR: Bombesin
antagonist-based radioligands for translational nuclear imaging of
gastrin-releasing peptide receptor-positive tumors. J Nucl Med.
52:1970–1978. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gourni E, Mansi R, Jamous M, Waser B,
Smerling C, Burian A, Buchegger F, Reubi JC and Maecke HR:
N-terminal modifi-cations improve the receptor affinity and
pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide
receptor antagonists: Examples of 68Ga- and 64Cu-labeled peptides
for PET imaging. J Nucl Med. 55:1719–1725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maina T, Nock BA, Zhang H, Nikolopoulou A,
Waser B, Reubi JC and Maecke HR: Species differences of bombesin
analog interactions with GRP-R define the choice of animal models
in the development of GRP-R-targeting drugs. J Nucl Med.
46:823–830. 2005.PubMed/NCBI
|
|
29
|
Fournier P, Dumulon-Perreault V,
Ait-Mohand S, Tremblay S, Bénard F, Lecomte R and Guérin B: Novel
radiolabeled peptides for breast and prostate tumor PET imaging:
(64)Cu/and (68) Ga/NOTA-PEG-[D-Tyr(6),
βAla(11),Thi(13),Nle(14)]BBN(6-14). Bioconjug Chem. 23:1687–1693.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lane SR, Nanda P, Rold TL, Sieckman GL,
Figueroa SD, Hoffman TJ, Jurisson SS and Smith CJ: Optimization,
biological evaluation and microPET imaging of copper-64-labeled
bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate
tumor xenografted mouse model. Nucl Med Biol. 37:751–761. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tokita K, Katsuno T, Hocart SJ, Coy DH,
Llinares M, Martinez J and Jensen RT: Molecular basis for
selectivity of high affinity peptide antagonists for the
gastrin-releasing peptide receptor. J Biol Chem. 276:36652–36663.
2001. View Article : Google Scholar : PubMed/NCBI
|
